Skip to Main Content

In the desperate search for ammunition to fend off the Covid-19 pandemic, a decades-old tuberculosis vaccine, given in huge numbers around the world, is gaining newfound attention.

Researchers in Australia and the Netherlands are testing the idea that the vaccine, known as BCG — short for bacille Calmette-Guérin — could have broad power to boost the immune system against the novel coronavirus. In the United States, a research group in Boston hopes to test the vaccine in frontline health workers for the same purpose.


The interest stems from multiple studies over a number of years that point to the vaccine as having what are known as “off-target” benefits.

While the vaccine, used in many low- and middle-income countries, isn’t considered to be highly effective against its primary goal, TB, it seems to help the immune system fend off various pathogens, including one that causes leprosy. The question is whether the virus known as SARS-CoV-2 is among them.

Not everyone is convinced.


A leading TB researcher, Madhukar Pai, has warned that the BCG vaccine is unlikely to be the magic bullet some people seem to think it may be. Pai, director of McGill University’s International TB Center, wrote a blog post over the weekend arguing that people may be ascribing almost magical powers to the vaccine.

“I think the idea is 100% worth investigating,” Pai said in an interview with STAT. “That’s why my piece was not against further research. My piece was saying: Right now we’re nowhere close to anything for a policy based on ecological studies that are full of holes.”

The World Health Organization seems to agree. On Sunday it published a scientific brief examining the evidence surrounding BCG. It concludes that there currently is no proof the vaccine protects against the new coronavirus. “In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19,” it stated.

Still, some researchers are hopeful.

Denise Faustman, director of immunobiology at Massachusetts General Hospital, has been studying BCG for years as a therapy for type 1 diabetes. She has a stash of the vaccine — which is not used in the United States for tuberculosis prevention — and wants to see if it could benefit frontline health workers. She is seeking institutional permission to quickly mount a trial at Boston’s Brigham and Women’s Hospital.

“The goal is to enroll rapidly over a two-month period, about 4,000 high-risk health care workers. And then the goal will be to watch them … to see if we can get a signal,” Faustman said.

The word has gotten around among health workers in Boston. Faustman’s phone is ringing off the hook. “Certainly the people who want in the trial are calling every five minutes [to ask], ‘How do I get in this trial?’” she said. “We have hundreds of phone calls right now of ‘Why can’t I get this?’”

In some respects, the notion of using a vaccine designed to prevent infection with one pathogen to protect people from another, unrelated bug seems counterintuitive. You wouldn’t expect a flu shot to offer any protection against Covid-19, for instance.

But years of research has suggested the immune system boost that BCG confers applies far more broadly than to just Mycobacterium tuberculosis, which causes TB. Children vaccinated with it in low- and middle-income countries around the world have been seen to have lower death rates from other respiratory infections, for instance.

Faustman is enthusiastic about the vaccine, hoping it will be shown to offer protection and could be used as a tool to safeguard critical health workers until a vaccine specifically developed to ward off Covid-19 infection is available. “That’s our goal.”

Pai agrees the study is worth doing. “Is there a signal to do additional research? I think the answer is yes. We’ve known that BCG has these non-specific effects against multiple [diseases],” he said.

But he also argues that proponents of using the vaccine to protect against Covid-19 are wrongly trying to ascribe differing death rates around the globe to a country’s use or non-use of BCG.

Pai and his group at McGill compiled the data everyone is making these inferences from, an online resource called the BCG World Atlas. It lists whether a country uses BCG, when the program was introduced or discontinued, and when it is given, among other things.

A number of studies, most of which have not yet gone through peer review, have suggested lower Covid-19 case numbers or death rates in some countries can be attributed to their use of BCG — drawing from the BCG Atlas.

“Suddenly everybody and their brother has found the atlas and then taken their Covid data from the WHO or from Johns Hopkins University or wherever, overlaid the two and run regression models and [said] ‘Oh, look here. BCG works,’” Pai said.

That kind of approach is flawed, he said, and doesn’t factor in that different outbreaks around the world are at different stages. That’s important because countries that have seen transmission more recently haven’t experienced the explosion of deaths seen in countries like Italy, Spain and the United States. Likewise, many low- and middle-income countries are not testing for Covid-19 in large numbers; their low case and death rates are more likely the result of under-reporting than of the BCG vaccine, Pai said.

The WHO’s statement also challenged the studies attempting to draw conclusions based on countries where BCG had been used. And it, too, pointed out that a run on the vaccine could create real damage. “BCG vaccination prevents severe forms of tuberculosis in children and diversion of local supplies may result in neonates not being vaccinated, resulting in an increase of disease and deaths from tuberculosis,” the global health agency said.

Pai worries that low- and middle-income countries that use BCG may buy into the untested hype around the vaccine and assume their populations have protection that they may not have. Only clinical trials can answer this question, he said.

“It would be dangerous for policymakers to assume protection from BCG and not act,” Pai said in his blog post in Forbes. “Researchers and journalists need to be responsible as well, and not raise false hopes based on weak evidence. And countries should not hoard BCG vaccines for Covid-19, since the BCG supply chain is weak, and really necessary to protect children in [low- and middle-income countries] from childhood TB.”

  • If we look at the BCG country statistics vs. the severity of COVID-19 the “coincidence” is striking.

    – In China it was intent to be applied to every child, but they skipped during the Great Leap and Cultural Revolution
    – In Germany it was mandatory in the East and merely “suggested” in the West. The COVID-19 statistics of residents in the former GDR vs. the former (“lesser”) FRG is striking.
    – In Italy it wasn’t even “suggested”.

    I can testify, the vaccination is quite painful, itchy and no fun for weeks. Depending on the country some series of tiny cuts was made on the shoulder or on the upper arm.

    The favorite “activity” of kids all over former “Communist” countries was to invent a reason why the vaccination should be postponed, we hated it that much.

    Parents usually did not wanted to listen to the “excuses” and things processed as mandated, not as we wanted.

    Much later, when my wife applied for a job in Cupertino School District she was first refused because according the tests she was infected by TBC.
    Than they realized, she is from a country where the BCG was mandatory and this “fools” the usual TBC tests in the States. She was re-tested using a different method and of course there was no TBC.

    But now you see the COVID-19 statistics in the “Wild East”, looks indeed like BCG vaccination did help both saving lives and make the infected suffer less.

    AFAIK, it is still mandatory in all ex-communist countries, except the post-reunification Germany. And China with it’s patchy history of BCG vs. the “pre-reunification” East Germany is the most apparent.

  • I was treated for Bladder Cancer 2 years ago with BCG therapy.The BCG was put into my bladder and I had to move around and then receive myself of the medicine. During one session the BCG therapy got into my blood stream and cause3d a severe reaction. I had a diagnosis of TB and had to take my meds infant of a county health worker. Upon further investigation by my Infectious Disease Doctor it was determined by more testing by NYS labs that I did not have TB,but BCG infection. I took all but one of the TB medications for 9 months and all is fine . My Bladder Cancer has since disappeared and has been for almost 18months.Getting the BCG therapy into my body made me very sick. i lent a week in the hospital being treated for Sepsus. I don’t think doctors knew what to do in the beginning of my problem, in the end i have been well.So far cancer is gone. BCG was only injected into bladder to stimulate an immune response. Getting the BCG into my blood stream was really bad. Still here. John V Murphy

  • Ms Bransell,

    Our group in Israel has published two articles, one hypothesis and one a test of the hypothesis. It is support of the concept that immunotherapy may prevent Alzheimer’s. No serious science writer has done a follow-up. In part Faustman’s work on T1D was the reason we pursued the idea. Although we recognized and quoted the country to country differences, we also found support in T1D, MS and multiple animal models.

    • Hi,

      The “crowned” statistics of former “socialist” countries is quite amazing.
      It is by no means a 100% recipe but the comparably very low number of victims looks convincing.

      The number of infected is huge and many believe, it is 8x to 10x as what is reported. This is not because the current governments would under-report it, this is not in their interest (China is the only exception). The typical process of a typical infection is that the infected would notice the change of the condition, report it to the doctor and the response will be: “stay at home and call, if it worsens”. No country is prepared and the hospitals need to take care of serious cases first. Therefore usually only people are tested who return from abroad or they start feel really bad. The rest (I assume the majority) who just does not feel good, but the condition is not life-threatening is not tested.

      While we do not know who is ill, but definitely know, who passed away. The numbers in “Wild East” where we, as new-Americans ultimately returned aren’t pretty. But probably thanks to BCG things do look better.

      I am afraid that my kids, who were born in the States do not have the BCG my wife and I do.

Comments are closed.